Literature DB >> 18358910

Perioperative chemotherapy for resectable hepatic metastases.

Scott Kopetz1, Jean-Nicolas Vauthey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18358910     DOI： 10.1016/S0140-6736(08)60429-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  19 in total

Review 1.  "Vanishing liver metastases"-A real challenge for liver surgeons.

Authors:  Alex Zendel; Eylon Lahat; Yael Dreznik; Barak Bar Zakai; Rony Eshkenazy; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Recent advances in the curative treatment of colorectal liver metastases.

Authors:  Andreas Andreou; Thomas A Aloia; Antoine Brouquet; Jean-Nicolas Vauthey
Journal:  Gastrointest Cancer Res       Date:  2011-07

3.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

4.  Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.

Authors:  G Passot; Y S Chun; S E Kopetz; M J Overman; C Conrad; T A Aloia; J-N Vauthey
Journal:  Eur J Surg Oncol       Date:  2016-03-05       Impact factor: 4.424

5.  RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Authors:  Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru
Journal:  Ann Surg       Date:  2013-10       Impact factor: 12.969

6.  Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy.

Authors:  Thomas A Aloia; Giuseppe Zimmitti; Claudius Conrad; Vijaya Gottumukalla; Scott Kopetz; Jean-Nicolas Vauthey
Journal:  J Surg Oncol       Date:  2014-05-21       Impact factor: 3.454

Review 7.  SSAT State-of-the-Art Conference: New Frontiers in Liver Surgery.

Authors:  Guido Torzilli; Masato Nagino; Ching-Wei D Tzeng; T Peter Kingham; Olusegun I Alatise; Omobolaji O Ayandipo; Suguru Yamashita; Amanda K Arrington; Joseph Kim; Yun Shin Chun; Jean-Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2016-08-01       Impact factor: 3.452

8.  Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?

Authors:  Antoine Brouquet; Michael J Overman; Scott Kopetz; Dipen M Maru; Evelyne M Loyer; Andreas Andreou; Amanda Cooper; Steven A Curley; Christopher R Garrett; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2011-03-28       Impact factor: 6.860

9.  Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings.

Authors:  Thomas J Semrad; Ana Rodriguez Fahrni; I-Yeh Gong; Vijay P Khatri
Journal:  Ann Surg Oncol       Date:  2015-06-23       Impact factor: 5.344

10.  Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.

Authors:  Junichi Shindoh; Evelyne M Loyer; Scott Kopetz; Piyaporn Boonsirikamchai; Dipen M Maru; Yun Shin Chun; Giuseppe Zimmitti; Steven A Curley; Chusilp Charnsangavej; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.